ISB researchers show that oxidative stress generated by the host immune system can prime tuberculosis bacteria to rapidly evolve antibiotic resistance, revealing how resistance may begin before treatment.
ISB researchers help reveal a previously hidden layer of the human proteome, identifying a new class of protein-like molecules known as “peptideins” with potential implications for cancer, immunotherapy, and human disease.
ISB researchers reveal a darker side of targeted therapy: the same oncogene inhibition that shuts down cancer growth program can also ignite a stress-driven identity switch — revealing an early escape route that may shape the future of cancer treatment
Institute for Systems Biology (ISB) is a collaborative and cross-disciplinary non-profit biomedical research organization based in Seattle. We focus on some of the most pressing issues in human health, including aging, brain health, cancer, COVID-19, as well as many infectious diseases. Our science is translational, and we champion sound scientific research that results in real-world clinical impacts. ISB is an affiliate of Providence, one of the largest not-for-profit health care systems in the United States.